Amgen's PCSK9 Patent Win: A Long-Term Value Shift?

Amgen Inc. may have won a battle in its lawsuit involving two patents on its proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor Repatha (evolocumab) against Sanofi SA and Regeneron Pharmaceuticals Inc., which market a competing drug, Praluent (alirocumab), but the California biotech giant is far from winning the war – that is, making the prophesied blockbuster profits on its medicine.

Amgen Inc. may have won a battle in its lawsuit involving two patents on its proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor Repatha (evolocumab) against Sanofi SA and Regeneron Pharmaceuticals Inc., which market a competing drug, Praluent (alirocumab), but the California biotech giant is far from winning the war – that is, making the prophesied blockbuster profits on its medicine.

In fact, both companies have struggled to gain wide acceptance in the prescriber community and nab the previously predicted pots...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip